CN118488840A - 治疗由非阿片样药剂调节的呼吸抑制的方法 - Google Patents

治疗由非阿片样药剂调节的呼吸抑制的方法 Download PDF

Info

Publication number
CN118488840A
CN118488840A CN202280080555.4A CN202280080555A CN118488840A CN 118488840 A CN118488840 A CN 118488840A CN 202280080555 A CN202280080555 A CN 202280080555A CN 118488840 A CN118488840 A CN 118488840A
Authority
CN
China
Prior art keywords
substituted
hours
compound
alkyl
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280080555.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·珀格利兹
T·米勒
A·施韦克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enara Treatment Co ltd
Original Assignee
Enara Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enara Treatment Co ltd filed Critical Enara Treatment Co ltd
Publication of CN118488840A publication Critical patent/CN118488840A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280080555.4A 2021-11-02 2022-11-02 治疗由非阿片样药剂调节的呼吸抑制的方法 Pending CN118488840A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274722P 2021-11-02 2021-11-02
US63/274,722 2021-11-02
PCT/US2022/048669 WO2023081185A1 (en) 2021-11-02 2022-11-02 Methods of treating respiratory depression modulated by a non-opioid agent

Publications (1)

Publication Number Publication Date
CN118488840A true CN118488840A (zh) 2024-08-13

Family

ID=86147248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280080555.4A Pending CN118488840A (zh) 2021-11-02 2022-11-02 治疗由非阿片样药剂调节的呼吸抑制的方法

Country Status (10)

Country Link
US (2) US12138267B2 (https=)
EP (1) EP4426308A4 (https=)
JP (1) JP2024540198A (https=)
KR (1) KR20240101622A (https=)
CN (1) CN118488840A (https=)
AU (1) AU2022380482A1 (https=)
CA (1) CA3236586A1 (https=)
MX (1) MX2024005389A (https=)
TW (1) TW202333730A (https=)
WO (1) WO2023081185A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
AU2011322147A1 (en) * 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2016007729A1 (en) 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
HK1245079A1 (zh) 2015-06-30 2018-08-24 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
EP3833346A4 (en) 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use

Also Published As

Publication number Publication date
AU2022380482A1 (en) 2024-05-16
JP2024540198A (ja) 2024-10-31
US20250032496A1 (en) 2025-01-30
EP4426308A1 (en) 2024-09-11
CA3236586A1 (en) 2023-05-11
US20230140606A1 (en) 2023-05-04
EP4426308A4 (en) 2025-09-03
MX2024005389A (es) 2024-07-09
US12138267B2 (en) 2024-11-12
WO2023081185A1 (en) 2023-05-11
TW202333730A (zh) 2023-09-01
KR20240101622A (ko) 2024-07-02

Similar Documents

Publication Publication Date Title
KR102382188B1 (ko) NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
CN119630402A (zh) 呼吸刺激剂鼻腔制剂
US20250114370A1 (en) Methods and compositions for treating drug overdose
JP2024517463A (ja) ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
JP6185773B2 (ja) 医薬組成物
KR20240150426A (ko) 비경구 호흡 자극제 제형
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
CN117479945A (zh) 大电导钾通道调节剂、其组合物、其制造方法及其使用方法
CN117529306A (zh) 烟酰胺腺嘌呤二核苷酸(nad)组合物、其制造方法及其使用方法
CN118829433A (zh) 呼吸刺激剂肠胃外制剂
TW202529771A (zh) 用於治療藥物過量的方法及組合物
JP2017190346A (ja) 医薬組成物
KR20170076105A (ko) 크립토탄시논을 유효성분으로 포함하는 안압 하강용 조성물
JP2017081825A (ja) メラニン産生抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination